Global Antifungal Drugs Market 2021

May 2021 | 31 pages | ID: GB6D9E671728EN
StrategyHelix Inc

Abstracts

Antifungal drugs are medications that are used to treat fungal infections. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The global antifungal drugs market in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 3.7% during the forecast period, according to data and analytics company StrategyHelix. North America is the most significant revenue contributor in the global antifungal drugs market. The region is expected to witness significant developments in the antifungal drugs market. Rise in awareness levels pertaining to myriad fungal infections, increasing prevalence of fungal infection, increasing number of people with weakened immune systems are the key factors driving market growth.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for antifungal drugs. The global antifungal drugs market is segmented on the basis of type, drug type, indication, and region. By type, it is categorized into prescription, and OTC. The OTC segment held the largest market share in 2020. By drug type, the antifungal drugs market is divided into echinocandins, polyenes, azoles, antimetabolites, and others. The azoles segment accounted for the largest market share in 2020. Based on indication, the antifungal drugs market is divided into dermatophytosis, aspergillosis, candidiasis, and others.

The report has profiled some of the key players of the market such as Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Gilead Sciences Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd..

Report Scope
Type: prescription, and OTC
Drug type: echinocandins, polyenes, azoles, antimetabolites, and others
Indication: dermatophytosis, aspergillosis, candidiasis, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global antifungal drugs market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global antifungal drugs market looks like
Identify the competitive landscape and window of opportunity

Contents

1. MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. MARKET DATA & OUTLOOK

3.1 Market Value
3.2 Market Value Forecast

4. ANTIFUNGAL DRUGS MARKET BY TYPE

4.1 Prescription
4.2 Otc

5. ANTIFUNGAL DRUGS MARKET BY DRUG TYPE

5.1 Echinocandins
5.2 Polyenes
5.3 Azoles
5.4 Antimetabolites
5.5 Others

6. ANTIFUNGAL DRUGS MARKET BY INDICATION

6.1 Dermatophytosis
6.2 Aspergillosis
6.3 Candidiasis
6.4 Others

7. ANTIFUNGAL DRUGS MARKET BY REGION

7.1 North America
7.2 Asia Pacific
7.3 Europe
7.4 Rest Of The World (Row)

8. COMPANY PROFILES

8.1 Astellas Pharma Inc.
8.2 Bausch Health Companies Inc.
8.3 Bayer AG
8.4 Dr. Reddy’s Laboratories Ltd.
8.5 Galderma S.A.
8.6 Gilead Sciences Inc.
8.7 Janssen Pharmaceuticals, Inc.
8.8 Merck & Co., Inc.
8.9 Pfizer Inc.
8.10 Teva Pharmaceutical Industries Ltd.

9. APPENDIX

9.1 About StrategyHelix
9.2 Disclaimer